Novo Nordisk

Choose the bypassing agent your hospital can count on for the most indications.

NovoSeven^® RT (coagulation Factor VIIa, recombinant) is indicated for: Treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets, and treatment of bleeding episodes and perioperative management in adults with acquired hemophilia

#1 prescribed bypassing agent in hospitals^3,c

AND the only rFVIIa approved for surgery in children and adults.^1,d

^aAdminister as a slow bolus injection over 2 to 5 minutes, depending on the dose administered.¹
^bCompassionate use, also known as expanded access, began enrolling in 1988; FDA approval for hemophilia A or B with inhibitors received in 1999.
^cBased on Acumetis data collected Q4 2024 through Q4 2025.³
^dPerioperative management in acquired hemophilia is indicated for adults only.

NovoSeven^® RT has been proven effective for bleed resolution and surgery across 5 indications—more than any other rFVIIa product^1,4

CHAwI | CHBwI | Acquired hemophilia | GT with refractoriness to platelets | CFVIId

Why NovoSeven^® RT

CFVIId=congenital factor VII deficiency; CHAwI=congenital hemophilia A with inhibitors; CHBwI=congenital hemophilia B with inhibitors; GT=Glanzmann’s thrombasthenia; rFVIIa=recombinant factor VIIa.

4 reasons your hospital can count on NovoSeven^® RT

Efficacy

Proven efficacy for bleed resolution and surgery across 5 indications—more than any other bypassing agent.^1,4-6

Predictable utilization

NovoSeven^® RT has one dosing regimen for patients with CHwI regardless of bleed severity. That consistent dosing may lead to predictable utilization.¹

Speed

Faster to infuse compared with FEIBA^® and Obizur^®.^1,5,6,e

Safety profile

Low rate of thrombotic adverse events based on clinical trials and registry data.¹

•	Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance. Thrombotic adverse reactions in pivotal clinical trials occurred in 0.2% of bleeding episodes in CHwI, 4% in AH, 0.8% in CFVIId, and <0.2% in GT with refractoriness to platelets.¹

^eAdminister NovoSeven^® RT as a slow bolus injection over 2 to 5 minutes, depending on the dose administered.¹ FEIBA^® should be injected or infused intravenously at a rate that does not exceed 10 units per kg of body weight per minute. For a dose of 75 U/kg, this equates to an infusion time of at least 7.5 minutes per kg of body weight.⁵ Administer Obizur^® intravenously at a rate of 1 to 2 mL per minute. For a 75-kg patient receiving a dose of 200 U/kg, this corresponds to an infusion time of 15 to 30 minutes.⁶

AH=acquired hemophilia, CHwI=congenital hemophilia with inhibitors

Scroll to see how NovoSeven^® RT continues to support your patients.

Important Safety Information

WARNING: THROMBOSIS

•	Serious arterial and venous thrombotic events following administration of NovoSeven^® RT have been reported

•	Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven^® RT

•	Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis

Warnings and Precautions

•	Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance

•

Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events

Please click here or scroll below for additional Important Safety Information.

NovoSeven^® RT for acute and emergent bleeding in the ER

•	For situations where patients have inhibitors, MASAC recommends that care should be urgently discussed with the patient’s hematologist. If in a life- or limb-threatening scenario, the safest immediate action is to prescribe rFVIIa at a dose of 90 mcg/kg or FEIBA^® at 75-100 units/kg.⁷
•	For CHAwI patients on emicizumab, MASAC recommends rFVIIa first; avoid FEIBA^® (pd-aPCC) if possible.⁸
•	If FEIBA^® is used in CHAwI patients on emicizumab, minimize duration; thrombosis and TMA may be associated with >24 hours usage above 100 units/kg/day.⁸

Efficient for your hospital pharmacy

•	Low-volume dosing and compact packaging to help maximize space.¹
•	Room temperature storage up to 77 °F.^1,f
•	The histidine diluent is provided in either a vial or prefilled diluent syringe.¹
•	Available in 1-mg, 2-mg, 5-mg, and 8-mg vials with everything needed for reconstitution in 1 box.¹

^fPrior to reconstitution, store NovoSeven^® RT powder and histidine diluent between 36-77 °F. After reconstitution, store NovoSeven^® RT either at room temperature or refrigerated for up to 3 hours. Do not freeze reconstituted NovoSeven^® RT or store in syringes.¹

NovoSeven^® RT has been building on more than 35 years of rFVIIa experience.^1,2

Learn more

Indications and Usage

NovoSeven^® RT (coagulation Factor VIIa, recombinant) is a coagulation factor indicated for:

•	Treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets

•	Treatment of bleeding episodes and perioperative management in adults with acquired hemophilia

Important Safety Information (cont’d)

Warnings and Precautions

•

Hypersensitivity reactions, including anaphylaxis, can occur with NovoSeven^® RT. Patients with a known hypersensitivity to mouse, hamster, or bovine proteins may be at a higher risk of hypersensitivity reactions. Discontinue infusion and administer appropriate treatment when hypersensitivity reactions occur

•

Factor VII deficient patients should be monitored for prothrombin time (PT) and factor VII coagulant activity (FVII:C). If FVII:C fails to reach the expected level, or PT is not corrected, or bleeding is not controlled after treatment with the recommended doses, antibody formation may be suspected and analysis for antibodies should be performed

•	Laboratory coagulation parameters (PT/INR, aPTT, FVII:C) have shown no direct correlation to achieving hemostasis

Adverse Reactions

•

The most common and serious adverse reactions in clinical trials are thrombotic events. Thrombotic adverse reactions following the administration of NovoSeven^® RT in clinical trials occurred in 4% of patients with acquired hemophilia and 0.2% of bleeding episodes in patients with congenital hemophilia

Drug Interactions

•	Thrombosis may occur if NovoSeven^® RT is administered concomitantly with Coagulation Factor XIII

Please click here for Prescribing Information, including Boxed Warning.

References:

1.	NovoSeven^® RT [package insert]. Plainsboro, NJ; Novo Nordisk Inc.
2.	Hedner U. History of rFVIIa therapy. Thromb Res. 2010;125(suppl 1):54-56.
3.	Data on file as of Q4 2025. Novo Nordisk Inc; Plainsboro, NJ.
4.	SEVENFACT^® [package insert]. Louisville, KY: HEMA Biologics, LLC; 2025.
5.	FEIBA^® [package insert]. Lexington, MA: Takeda Pharmaceuticals U.S.A., Inc; 2024.
6.	Obizur^® [package insert]. Westlake Village, CA: Baxter Healthcare Corporation; 2024.
7.	National Bleeding Disorders Foundation. Guidelines for emergency department management of individuals with hemophilia and other bleeding disorders. MASAC document #257. Approved December 2, 2019. Adopted December 5, 2019. Accessed June 23, 2026. https://www.hemophilia.org/healthcare-professionals/guidelines-on-care/masac-documents/masac-document-257-guidelines-for-emergency-department-management-of-individuals-with-hemophilia-and-other-bleeding-disorders
8.	MASAC recommendation on the use and management of emicizumab-kxwh (Hemlibra^®) for hemophilia A with and without inhibitors. MASAC Document #268. Accessed August 9, 2023. https://www.hemophilia.org/healthcare-professionals/guidelines-on-care/masac-documents/masac-document-268-recommendation-on-the-use-and-management-of-emicizumab-kxwh-hemlibrar-for-hemophilia-a-with-and-without-inhibitors

Please click on the link to see WAC pricing for the product mentioned above: Product Pricing.

Please do not respond to this email. If you would like to contact us, please click here or call 1-800-727-6500.

NovoSeven^® is a registered trademark of Novo Nordisk Health Care AG.
novoMEDLINK™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their respective owners.
© 2026 Novo Nordisk All rights reserved. US26NSVN00014 July 2026